Christopher Ogden - 26 Sep 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CTMX
Reported as of: 26 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Sep 2025, 18:38:27 UTC
Prior SEC filing: 17 Jun 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Ogden

Key filing fact

Christopher Ogden filed Form 4 for CytomX Therapeutics, Inc. (CTMX) on 30 Sep 2025.

Key facts

This page summarizes Christopher Ogden's Form 4 filing for CytomX Therapeutics, Inc. (CTMX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 30 Sep 2025, 18:38.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001914523 Primary reporting owner

Ogden Christopher

Relationship: Chief Financial Officer
Address: C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO
Signature: /s/ Christopher Ogden
Signature date: 30 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTMX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +78,250
Change %
Price: $0.000000
Shares after: 78,250
Date: 26 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 78,250
Exercise price: $2.90
Footnotes: F1

CTMX transaction Derivative

Performance Stock Units (PSUs)

Award

Transaction value: $0
Shares: +39,150
Change %
Price: $0.000000
Shares after: 39,150
Date: 26 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 39,150
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Footnote F2

Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.